» Articles » PMID: 24373158

Self-processing of Ribozyme-flanked RNAs into Guide RNAs in Vitro and in Vivo for CRISPR-mediated Genome Editing

Overview
Specialty Biology
Date 2013 Dec 31
PMID 24373158
Citations 244
Authors
Affiliations
Soon will be listed here.
Abstract

CRISPR/Cas9 uses a guide RNA (gRNA) molecule to execute sequence-specific DNA cleavage and it has been widely used for genome editing in many organisms. Modifications at either end of the gRNAs often render Cas9/gRNA inactive. So far, production of gRNA in vivo has only been achieved by using the U6 and U3 snRNA promoters. However, the U6 and U3 promoters have major limitations such as a lack of cell specificity and unsuitability for in vitro transcription. Here, we present a versatile method for efficiently producing gRNAs both in vitro and in vivo. We design an artificial gene named RGR that, once transcribed, generates an RNA molecule with ribozyme sequences at both ends of the designed gRNA. We show that the primary transcripts of RGR undergo self-catalyzed cleavage to generate the desired gRNA, which can efficiently guide sequence-specific cleavage of DNA targets both in vitro and in yeast. RGR can be transcribed from any promoters and thus allows for cell- and tissue-specific genome editing if appropriate promoters are chosen. Detecting mutations generated by CRISPR is often achieved by enzyme digestions, which are not very compatible with high-throughput analysis. Our system allows for the use of universal primers to produce any gRNAs in vitro, which can then be used with Cas9 protein to detect mutations caused by the gRNAs/CRISPR. In conclusion, we provide a versatile method for generating targeted mutations in specific cells and tissues, and for efficiently detecting the mutations generated.

Citing Articles

CRISPR-Cas9-based one-step multiplexed genome editing through optimizing guide RNA processing strategies in .

Chen K, Maimaitirexiati G, Zhang Q, Li Y, Liu X, Tang H Synth Syst Biotechnol. 2025; 10(2):484-494.

PMID: 39995681 PMC: 11847659. DOI: 10.1016/j.synbio.2025.01.005.


Ultrasound Control of Genomic Regulatory Toolboxes for Cancer Immunotherapy.

Wu Y, Huang Z, Liu Y, He P, Wang Y, Yan L Nat Commun. 2024; 15(1):10444.

PMID: 39617755 PMC: 11609292. DOI: 10.1038/s41467-024-54477-7.


CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer.

Noruzi S, Mohammadi R, Jamialahmadi K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39560750 DOI: 10.1007/s00210-024-03480-2.


Improving the Genome Editing Efficiency of CRISPR/Cas9 in Melon and Watermelon.

Wang Z, Wan L, Ren J, Zhang N, Zeng H, Wei J Cells. 2024; 13(21.

PMID: 39513889 PMC: 11544962. DOI: 10.3390/cells13211782.


Reconstructing signaling history of single cells with imaging-based molecular recording.

Hao K, Barrett M, Samadi Z, Zarezadeh A, McGrath Y, Askary A bioRxiv. 2024; .

PMID: 39416000 PMC: 11482953. DOI: 10.1101/2024.10.11.617908.